Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs intermittent weekly docetaxel in elderly patients with advanced hormone-refractory prostate cancer
2008-001632-13Phase 2Active
- Sponsor
- Lega Italiana per la Lotta contro i Tumori
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of docetaxel in prostate cancer (PCa) (3 arms), sponsored by Lega Italiana per la Lotta contro i Tumori. Primary endpoints: Quality of life and Overall survival. Started Mar 2009; status: active.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-001632-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001632-13.